Sun Pharma Q1 FY27 Results reported a strong start to FY2027, with consolidated revenue increasing 10.1% year-on-year to ₹151,836 million. Growth was driven by the India formulations business, innovative medicines, and specialty products despite continued pressure in the U.S. generics market.
Sun Pharma Q1 FY27 Results: Quick Summary
Sun Pharma reported ₹151,836 million in consolidated revenue for Q1 FY27, reflecting 10.1% year-on-year growth. India formulations grew 16%, innovative medicines increased 12.8%, and EBITDA reached ₹44,177 million with a 28.9% margin. Despite weaker U.S. generics sales, the company maintained strong profitability and continued expanding its research pipeline and specialty business.
Sun Pharma Q1 FY27 Results Overview
| Particular | Q1 FY27 Performance |
|---|---|
| Company | Sun Pharmaceutical Industries Ltd. |
| Reporting Period | Q1 FY2026-27 (Quarter Ended June 30, 2026) |
| Consolidated Revenue | ₹151,836 Million |
| Revenue Growth | 10.1% YoY |
| Net Profit | ₹28,948 Million |
| Adjusted Net Profit | ₹30,894 Million |
| EBITDA | ₹44,177 Million |
| EBITDA Margin | 28.9% |
Financial Highlights
Sun Pharma delivered strong financial performance during the first quarter.
Key Highlights
- Revenue increased by 10.1% YoY
- Net profit reached ₹28,948 million
- Adjusted net profit stood at ₹30,894 million
- EBITDA increased to ₹44,177 million
- EBITDA margin remained strong at 28.9%
The results demonstrate continued operational strength despite challenging market conditions in the U.S. generics business.
India Business Continues to Lead Growth
The domestic formulations business remained Sun Pharma’s largest revenue contributor.
| Particular | Performance |
|---|---|
| India Sales | ₹54,749 Million |
| Growth | 16% YoY |
| Contribution to Total Sales | 36.1% |
| Market Share | 8.5% |
| New Products Launched | 5 |
Sun Pharma retained its leadership position in the Indian pharmaceutical market while expanding its market share and launching five new products during the quarter.
Innovative Medicines Deliver Strong Growth
Sun Pharma’s innovative medicines portfolio continued to perform well.
| Particular | Performance |
|---|---|
| Global Innovative Medicines Sales | US$351 Million |
| Growth | 12.8% YoY |
| Contribution to Total Sales | 21.9% |
The strong performance reflects the company’s continued focus on specialty medicines and innovative therapies.
External API Business and Research Investment
Sun Pharma continued investing in research and manufacturing capabilities.
| Particular | Performance |
|---|---|
| External API Sales | ₹5,972 Million |
| Growth | 10.5% |
| R&D Expenditure | ₹8,264 Million |
| R&D as % of Sales | 5.4% |
The company continues to strengthen its research capabilities to support future product development.
| Metric | Q1 FY27 |
|---|---|
| Revenue | ₹151,836 Million |
| Revenue Growth | 10.1% |
| India Business | +16% |
| Innovative Medicines | +12.8% |
| EBITDA Margin | 28.9% |
U.S. Business Performance
The U.S. formulations business remained challenging during the quarter.
| Particular | Performance |
|---|---|
| U.S. Formulations Sales | US$427 Million |
| Growth | -9.7% YoY |
According to the company, growth in innovative medicines partially offset the decline in the U.S. generics business.
Emerging Markets Performance
International markets continued to contribute to overall growth.
| Market | Sales |
|---|---|
| Emerging Markets | US$311 Million |
| Growth | 4.2% |
| Rest of World | US$218 Million |
Pipeline and Regulatory Progress
Sun Pharma continues expanding its research and regulatory portfolio.
Pipeline Highlights
- Five novel molecules under clinical development.
- 558 approved ANDAs in the U.S.
- 119 ANDAs awaiting FDA approval.
- 28 tentative approvals.
- Three ANDAs filed during the quarter.
- Six ANDAs approved.
- 57 approved NDAs.
- 13 NDA applications under FDA review.
The company also reported progress for:
- Ilumya
- Fibromun
- GL0034 (Type 2 Diabetes)
- Nidlegy
These developments strengthen Sun Pharma’s specialty medicine portfolio.
Organon Acquisition Update
Managing Director Kirti Ganorkar stated that strong performance in India and innovative medicines supported quarterly growth.
He also confirmed:
- Organon shareholders have approved the proposed acquisition.
- The acquisition remains on track for completion in early 2027.
- Sun Pharma recently received approvals for semaglutide products in India, Brazil, and South Africa, strengthening its position in complex peptide therapies.
Key Takeaways
- Revenue increased 10.1%.
- India business grew 16%.
- Innovative medicines rose 12.8%.
- EBITDA margin reached 28.9%.
- U.S. generics remained under pressure.
- Strong investment continues in R&D and specialty medicines.
- Organon acquisition remains on schedule.
Why Is This Important for the Pharmaceutical Industry?
Sun Pharma’s latest quarterly performance highlights several important trends:
- Continued strength in India’s pharmaceutical market.
- Increasing contribution from innovative medicines.
- Growing investment in specialty therapies.
- Expansion of the global regulatory pipeline.
- Long-term focus on research-driven growth.
These developments demonstrate how leading pharmaceutical companies are balancing traditional generics with innovative therapies to drive sustainable growth.
Frequently Asked Questions (FAQs)
1. How much revenue did Sun Pharma report in Q1 FY27?
Sun Pharma reported consolidated revenue of ₹151,836 million, representing 10.1% year-on-year growth.
2. How much did the India business grow?
India formulations sales increased 16% year-on-year to ₹54,749 million.
3. What was Sun Pharma’s EBITDA margin?
The company reported an EBITDA margin of 28.9%.
4. How did innovative medicines perform?
Global innovative medicines sales reached US$351 million, growing 12.8% year-on-year.
5. What happened in the U.S. market?
The U.S. formulations business declined 9.7%, mainly due to weaker generics sales.
6. How much did Sun Pharma invest in R&D?
The company invested ₹8,264 million, representing 5.4% of total sales.
7. What is the status of the Organon acquisition?
The proposed acquisition has received shareholder approval and is expected to be completed in early 2027.
8. Why are Sun Pharma’s Q1 FY27 results important?
The results demonstrate strong growth in India, continued momentum in innovative medicines, sustained investment in research, and long-term expansion through specialty products and acquisitions.
Conclusion
The Sun Pharma Q1 FY27 Results demonstrate the company’s strong financial position and strategic focus on innovation, specialty medicines, and global expansion. While the U.S. generics business remained challenging, robust growth in India, higher sales of innovative medicines, and continued investment in research and development helped drive overall performance. With an expanding product pipeline and the planned Organon acquisition, Sun Pharma remains well-positioned for long-term growth in the global pharmaceutical industry.
Recommended Products
